Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07216586 · ClinicalTrials.gov registry record · Phase 4
Zynrelef Versus Adductor Canal Block
A Phase 4 study, sponsored by University of Miami.
- Not yet
- Registry status
- Phase 4
- Development phase
- 120
- Enrollment target
NCT07216586 is a Phase 4 study that has not yet begun recruiting, run by University of Miami. The registered enrollment target is 120 participants.
The verdict
NCT07216586, a Phase 4 study, has not yet begun recruiting, sponsored by University of Miami.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 120 participants
- Enrollment target
Study Summary
To compare postoperative MME consumption 72 hours after TKA in patients receiving intraoperative periarticular HTX-011 (Zynrelef) instillation versus adductor canal block.
Interventions
- DRUG Ropivacaine 0.5% Injectable Solution
- DRUG ZYNRELEF 400Mg-12Mg Extended-Release Solution
- PROCEDURE Ultrasound-Guided Adductor Canal Block
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2027-01 |
| Est. Completion | 2028-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07216586
The ClinicalTrials.gov registry entry for NCT07216586 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ropivacaine 0.5% Injectable Solution is the first listed.
NCT07216586 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07216586 about?
NCT07216586 is a clinical study titled "Zynrelef Versus Adductor Canal Block". To compare postoperative MME consumption 72 hours after TKA in patients receiving intraoperative periarticular HTX-011 (Zynrelef) instillation versus adductor canal block.
What is the current status of trial NCT07216586?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2027-01. Estimated completion is 2028-01.
What interventions are being tested in trial NCT07216586?
The interventions under investigation include: Ropivacaine 0.5% Injectable Solution (DRUG), ZYNRELEF 400Mg-12Mg Extended-Release Solution (DRUG), Ultrasound-Guided Adductor Canal Block (PROCEDURE).
Who is sponsoring clinical trial NCT07216586?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.